Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Iparomlimab + Tuvonralimab + TACE Conversion Therapy in Potentially Resectable HCC
ChiCTR2500115667Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib, iparomlimab and tuvonralimab in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Conversion success rate. Started Dec 2025; status: recruiting.
02
Drugs
lenvatinibiparomlimabtuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500115667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115667.